A randomized clinical trial was conducted between July 2015 and November 2016. A total of 226 patients who underwent elective valvular surgery were randomly assigned to the ERAS pathway or routine care (control) group. The ERAS protocol consisted of an evidence-based systematic optimization approach for managing perioperative patients. The control group received routine care. The primary end-point was readiness for hospital discharge. The secondary outcomes were duration of intensive care unit (ICU) stay, length of postoperative vasoactive drug support, duration of mechanical ventilation, time to first bowel movement, removal of surgical drain, overall medical costs and complication rate.
INTRODUCTION
The concept of enhanced recovery after surgery (ERAS) was first reported by Kehlet [1] in 1997. Enhanced recovery refers to a series of evidence-based perioperative care pathways designed to reduce physiological and psychological stress in surgical patients and to achieve rapid recovery [2] . The interventions cover the entire spectrum of the surgical experience, including the preoperative, intraoperative and postoperative periods [3] . Most published data on ERAS have been in colorectal surgery. ERAS pathways have been increasingly widely adopted in other surgical procedures. However, there is a paucity of data on the use of ERAS in cardiac surgery.
Patients undergoing cardiac surgery experience physiological stress, an inflammatory response with potentially high complication rates. Elements of enhanced recovery could ameliorate surgical stress and would be well suited for patients undergoing cardiac surgery. Therefore, we conducted this study to evaluate the impact of an ERAS protocol in patients undergoing cardiac surgery. The primary hypothesis is that the adoption of ERAS pathways in patients undergoing cardiac valve surgery reduces the time to readiness for hospital discharge.
MATERIALS AND METHODS

Trial design and participants
This single-centre, randomized controlled trial was conducted at Xiangya Hospital, Central South University, China. The study protocol and the consent form were approved by the institutional ethics committee of Xiangya Hospital of Central South University (approval number 201504491). The study was registered at ClinicalTrials.gov (NCT02479581). Informed consent for participation in the study was obtained from all patients.
Patients were included if they were between 18 and 70 years of age, had a body mass index of 15-30 kg/m 2 and were receiving elective heart valve surgery. Perioperative risk was calculated by the Society of Thoracic Surgeons (STS) Online Risk Calculator [4] . The exclusion criteria were as follows: a New York Heart Association (NYHA) class of heart function of IV; an international normalized ratio >2.0; a history of stroke; creatinine levels >300 lmol/l; an abnormal liver function test, such as a decreased synthesis of liver proteins such as albumin and clotting factors; presence of endocrine disease, such as thyroid and adrenal diseases; presence of infection; severe mental disorder; emergent surgery; existing pacemaker; a history of alcohol and drug abuse and patient refusal.
A total of 230 patients who underwent cardiac valve surgery were evaluated for eligibility between July 2015 and November 2016. Four patients were excluded after the initial assessment; hence, 226 eligible patients were randomized. Randomization was performed by independent personnel based on a computergenerated random digit table. Permuted block randomization was used with a block size of 2 and an allocation ratio of 1:1. Seventeen patients were excluded from the study after randomization for not meeting the inclusion criteria or refusing surgery or participation in the trial. Of the remaining patients, 105 received conventional standard care, and 104 received protocolized care (Fig. 1) .
Each patient was followed up by a research coordinator to ensure strict compliance with the protocol. Patients in the ERAS group received all elements of the ERAS protocol. Intraoperative and postoperative adverse events were recorded. The patients were followed up at 1, 3 and 6 months after hospital discharge.
CLINICAL PATHWAY
Preoperative elements of the enhanced recovery after surgery protocol Patients in the ERAS group received a detailed explanation of their perioperative care and a health manual. Education and psychological counselling were conducted by trained staff. Approximately 5 days before surgery, patients without contraindications in the ERAS group received a recombinant human erythropoietin (rhEPO) injection (Harbin Pharmaceutical Group Holding Co. Ltd, Harbin, China) to increase postoperative haemoglobin levels. Preoperative bowel preparation and preoperative sedative use were not administered. The nil per os time was reduced from the conventional 12 h to 6 h with light meals. Patients received 250 ml of oral carbohydrate solution containing 25 g glucose 2 h before surgery. Prophylactic antibiotics were administered within 60 min of surgical incision (Table 1) .
Intraoperative elements of the enhanced recovery after surgery and anaesthesia protocol For the ERAS group, patients received general anaesthesia after administration of a paravertebral nerve block. Paravertebral blocks were performed at the T2-3 and T5-6 levels prior to induction of anaesthesia. A total of 8-10 ml of 0.25% plain ropivacaine was injected at each site. All patients received sufentanil, vecuronium and etomidate for induction. Anaesthesia was maintained with continuous infusion of propofol, remifentanil, vecuronium and sevoflurane. Hydromorphone was administered before skin closure. A bispectral index (Aspect Medical Systems, Inc., Norwood, MA, USA) monitor was used to maintain the depth of sedation at a bispectral index score of 40-55. After mechanical ventilation was initiated, a lung protection strategy, including low tidal volume ventilation and positive end-expiratory pressure in addition to lung recruitment manoeuvres during the entire operation, was used. Goal-directed fluid therapy was used to optimize stroke volume guided by transoesophageal echocardiography (Vivid 7, GE Medical System, Norway). Each patient received cardiopulmonary bypass (CPB), with some procedures strictly used, such as total priming fluid reduction, plasma albumin infusion, retrograde oxygenated warm blood cardioplegia perfusion in addition to St. Thomas' antegrade cold blood cardioplegia perfusion and modified ultrafiltration, to maintain a stable plasma colloid osmotic pressure and myocardial protection. Continuous near-infrared spectroscopy to monitor cerebral oxygen saturation (Chongqing Medical Equipment Co. Ltd, Chongqing, China) was used to enable timely adjustment of cerebral perfusion flow and haemoglobin concentration during CPB. Thromboelastography (TEG-HAEMONETICS TEG5000, Boston, MA, USA) was used to assess coagulopathy after weaning from CPB and protamine administration. Blood conservation measures such as cell saver (Haemonetics Corporation, Braintree, MA, USA) and aminocaproic acid 20 mg/kg/h (Shanghai Xinyi Jinzhu Pharma. Co. Ltd, Shanghai, China) were administered. Red blood cells were transfused when the patients' haemoglobin was below 8 g/dl. Routine care was used in the control group (Table 1) .
Postoperative elements of the enhanced recovery after surgery protocol Postoperatively, patients in both groups received intravenous patient-controlled analgesia with sufentanil. In the ERAS group, patients received an additional 20 ml of 0.25% ropivacaine administered by local infiltration around the incision site. Ondansetron was used to reduce the risk of postoperative nausea and vomiting. Oral fluid was commenced within 6 h of extubation, and a full diet was started on the 1st day after extubation in the intensive care unit (ICU). Urinary catheters and thoracic drainage tubes were removed as soon as possible on postoperative day 1 instead of on postoperative day 2 or 3 as in the control group, and patients were encouraged to ambulate as soon as possible. rhEPO administration was continued after surgery until the patient's haemoglobin level was above 10 g/dl. Patients in the control group received the conventional perioperative protocol (Table 1) .
Patients were discharged from the ICU when they met the institutional discharge criteria (were fully conscious, breathing spontaneously with a peripheral capillary oxygen saturation >90% with room air, and not receiving intravenous infusion of vasoactive drugs to maintain haemodynamic stability and had a urine volume > _1 ml/kg/h, a drainage volume <50 ml/h and no serious cardiac arrhythmias). The assessments were performed by ICU physicians blinded to the groups.
When readiness for discharge criteria were met, patients were discharged home. The criteria included stable cardiac rhythm, ability to tolerate oral fluid and solid food, adequate pain control without the need for intravenous analgesia, independent mobilization, temperature within a normal range, established urination and defaecation, no drainage tubes, normal wound healing, no major complications requiring hospital stay, laboratory tests within normal limits and a transthoracic echocardiography that confirmed good valvular function. The assessments were performed by an independent surgeon on the ward who was unaware of the group assignments.
Study end-points
The primary end-point of the study was time to readiness for hospital discharge, as defined above. The secondary end-points were length of ICU stay, time to first bowel movement and hospitalization costs (all hospitalization expenses except the cost of the artificial valve). The duration of postoperative mechanical ventilation, use of vasoactive drug support (dopamine, noradrenaline and adrenaline), time to first full diet, time to drainage tube removal, visual analogue scale pain score, results of major laboratory tests, adverse events during hospitalization, long-term (6 months) complications and patient satisfaction were also recorded. Intraoperative variables such as blood pressure, heart rate, oxygen saturation, the bispectral index, cerebral oxygen saturation and heart function were recorded and compared. After surgery, the haemodynamics, haemoglobin concentration, body temperature, C-reactive protein concentration and procalcitonin, N-terminal pro-brain natriuretic peptide, glucose and lactic acid values were also recorded.
The 8-item short-form health survey (SF-8) was performed before surgery and at 1, 3 and 6 months after hospital discharge. Lower scores indicate worse health-related quality of life. A postoperative follow-up phone call with a family member was conducted to assess the patient's daily activity and occurrence of readmission. 
Statistical analysis
Statistical analyses were performed with GraphPad Prism V R (version 5.01, GraphPad Software, San Diego, CA, USA). The sample size was calculated using Statistics Analysis System 9.4 (SAS Institute Inc., Iowa city, IA, USA). Based on existing hospital data, we estimated that the ERAS protocol would reduce the length of stay by 1 day compared to that of the control, with an SD of 1.5 days. Accordingly, 98 patients were required per group. To account for a 20% dropout rate, we enrolled 113 subjects per group. The significance level of the test was set to 0.05, and the statistical power was 90%. The values were expressed as the mean ± standard deviation.
The rates of mortality and morbidity in the ERAS and control groups were compared using the v 2 test or the Fisher's exact test. The Kolmogorov-Smirnov test was used to evaluate whether the continuous variables were normally distributed. Perioperative haemodynamic data and patient characteristics with a normal distribution were compared between the 2 groups using a 2-sample Student's t-test. Data without a normal distribution were analysed using the Mann-Whitney U-test. P-values <0.05 were considered statistically significant.
RESULTS
Regarding patient demographics and other characteristics, the control group and ERAS group were similar in age, gender, BMI, STS score, American Society of Anesthesiologists (ASA) physical status and NYHA class of heart function ( Table 2) . No difference was observed in the preoperative health-related quality-of-life questionnaire (SF-8) score (Supplementary Material, Table S1) or surgery type between the 2 groups. There were 4 patients in each group who had valvular disease and concomitant coronary artery disease. They were diagnosed by coronary angiography preoperatively (Table 3) .
Intraoperative heart rate was significantly lower in the ERAS group than in the control group. Other haemodynamic variables were comparable intraoperatively and postoperatively (Supplementary  Material, Tables S2 and S3 ). The extent of adherence to protocol elements is shown in Supplementary Material, Table S4 .
The primary outcome and secondary outcomes of the ERAS group were significantly lower than those of the control group Values are in parameter counts n (%). CABG: coronary artery bypass grafting; ERAS: enhanced recovery after surgery.
( Table 4 ). Postoperative haemoglobin concentration was higher and allogeneic red blood cell usage was lower in the ERAS group. Inflammatory biomarkers, e.g. C-reactive protein, procalcitonin and N-terminal pro-brain natriuretic peptide, were higher postoperatively in the control group than in the ERAS group (Table 5 ). The incidence of major complications, such as acute renal failure, postoperative delirium (evaluated with CAM-ICU) and cardiac and cerebral vascular events (permanent or transient stroke, coma, perioperative myocardial infarction, heart block or cardiac arrest), was lower in the ERAS group (Table 6 ). The postoperative visual analogue scale score in the ERAS group was significantly lower than that in the control group. The number of patients with a visual analogue scale score > _4 and <4 significantly differed between the 2 groups (Supplementary Material, Table S5 ).
No difference was observed in the healthy life questionnaire (SF-8) scores between the groups at 1, 3 and 6 months after discharge (Supplementary Material, Table S1 ). There was no difference in other major adverse events at 1 and 6 months after discharge (Supplementary Material, Table S6 ).
DISCUSSION
We chose to assess surgical valve patients in this study because valvular disease is the most common reason for cardiovascular surgery in China. Our study showed that the time to readiness for hospital discharge and duration of ICU stay in the ERAS group were significantly shorter than the corresponding values in the control group. Patients cared for under the ERAS protocol appeared to have superior clinical outcomes at a reduced cost. The ERAS protocol is a bundle of evidence-based perioperative Values are expressed as the mean ± standard deviation. CRP: C-reactive protein; ERAS: enhanced recovery after surgery; HB: haemoglobin; INR: international normalized ratio; NT-proBNP: N-terminal pro-brain natriuretic peptide; PCT: procalcitonin; Scr: serum creatinine. approaches that aim to alleviate postoperative functional disorders by reducing surgical stress and promoting postoperative recovery [3, 5, 6] . A series of clinical trials and meta-analyses have confirmed the effectiveness of ERAS in a variety of non-cardiac surgeries [7] . In the early 1990s, the 'fast-track' approach was widely used in cardiac surgery [8, 9] . However, there is a major difference between the 'fast-track' approach and the more comprehensive ERAS pathways. The 'fast-track' approach concentrated on modifying the anaesthetic and surgical technique, e.g. shorter acting anaesthetic agents and minimally invasive incisions to achieve early extubation and shorter ICU stays. However, the ERAS pathways incorporate a series of perioperative optimizations of patient care to accelerate postoperative recovery. The results from ERAS pathways demonstrate a greater impact on postoperative outcomes than the effects of the traditional 'fast-track' approach. Preoperative education and psychological counselling are designed to alleviate patient anxiety and to improve patient compliance. Decreasing the preoperative fasting period increases patient comfort. Providing a carbohydrate beverage 2 h before commencement of anaesthesia has been shown to reduce the risk of intra-and postoperative insulin resistance [10] . Postoperative anaemia is a recognized risk factor for surgical mortality [11] . Preoperative use of iron or rhEPO has been shown to reduce postoperative anaemia and usage of red blood cells [12, 13] . With the use of rhEPO, our study found that the haemoglobin concentration was higher in the ERAS group with less usage of blood products during the perioperative period. Most of the heart valve surgery involves median sternotomy, and hence, large doses of opioids are needed for analgesia. We found that the bilateral thoracic paravertebral nerve block reduced the consumption of opioids as same as ever reported [14] . We adopted the currently accepted intraoperative lung protection strategy, including low tidal volume combined with positive end-expiratory pressure [15] and application of alveolar recruitment manoeuvres, to mitigate lung injury and atelectasis. Anti-inflammation therapy, maintenance of colloid osmotic pressure during CPB and implementation of ultrafiltration at the end of CPB can decrease pulmonary oedema [16] . Our observations confirmed that these interventions were helpful in reducing postoperative pulmonary complications. Goal-directed fluid therapy has been incorporated into many ERAS protocols [17, 18] . However, its efficacy has been debated. During CPB and in the presence of hypothermia, exposure of the patient's blood to an extracorporeal circuit and blood dilution activates abnormal coagulation reactions and promotes inflammation and oxidative stress reactions. Decreasing the CPB priming volume and the application of ultrafiltration technology can maintain colloid osmotic pressure and reduce inflammation. We found a reduction in biomarkers of inflammation in the ERAS group. All of these approaches may contribute to a shorter duration of mechanical ventilation. Thromboelastography has been widely used to monitor coagulation and guide rational blood product therapy [19] . We believe that the use of this technique helped us manage coagulation more effectively and achieve a shorter duration to chest drainage removal. To detect intraoperative cerebral low perfusion and determine imbalances in cerebral oxygen supply and demand, regional cerebral tissue oxygen saturation (rSO2%) monitoring was used and can reduce the incidence of cerebral complications [20] . Postoperative pain interferes with patient rehabilitation. Adequate analgesia can effectively reduce perioperative stress and improve patient comfort and recovery. The results of this study showed that the ERAS protocol resulted in an earlier return to gastrointestinal function and early recovery. Early mobilization has been shown to promote recovery of physiological function [21, 22] . In this study, improvement in pain management and the prompt removal of drains made early ambulation possible. Some surgeons most frequently suspect that the 1st day after surgery is too early to remove the chest tube even when there is no obvious bleeding. More evidence, such as findings from ultrasound, should be used to guide the early removal of drainage. Some patients were reluctant to adhere to early mobilization. They needed more encouragement and help. It has been reported that postoperative physical therapy for thoracic surgery could reduce 30-day mortality or the incidence of postoperative pulmonary complications [23] . Postoperative physical therapy and rehabilitation exercises in the ERAS programme could enable patients to resume their normal activities. The SF-8 qualityof-life questionnaires reflect patients' subjective feelings regarding their quality of life. In our study, the ERAS protocol did not influence the results of this quality-of-life evaluation between the 2 groups.
We did not find a statistically significant difference in the actual length of postoperative hospital stay. This may be related to the healthcare system in China, where patients may not be able to be discharged due to inadequate home support. Many patients live a considerable distance away from the hospital and may not be able to leave the hospital on the day when they are deemed ready to be discharged.
The level of protocol compliance has been associated with the improvement in outcomes, with a higher degree of compliance producing better results. We were able to achieve a high level of compliance with the ERAS protocol. This may be related to the fact that the protocol was supported by multidisciplinary teams, including surgeons, anaesthesiologists, nursing and support staff.
Limitations
There are limitations to this study that should be considered. Patients >70 years, those with a BMI >30 kg/m 2 and critical patients were excluded because of patient safety considerations. We limited our population to patients undergoing cardiac valvular surgery. Although this was a randomized controlled trial, total blinding was not possible; however, blinding was achieved in the personnel who collected the data, patients, ICU physicians, surgeons on the ward and the statisticians. We were confident that the data collected were not biased towards either of the groups. Rehabilitation was conducted in local hospitals after discharge, and we did not collect data for this phase. Additional limitations include the single-centre nature of this study and the inclusion of only ASA Grade II and III patients in the study.
CONCLUSIONS
This study demonstrates that patients undergoing cardiac valvular surgery who receive an ERAS protocol had a shorter readiness for hospital discharge time, shorter length of ICU stay and reduced costs. Larger, multicentre studies should be conducted to validate our findings.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
